Lipoprotein(a), or Lp(a), is a cholesterol-carrying particle in your blood that combines a low-density lipoprotein (LDL) particle with a second protein called apolipoprotein(a). It is important because high Lp(a) is an inherited, largely lifelong risk factor for heart attack, stroke, and narrowing of the aortic valve, and standard cholesterol tests usually do not measure it.
The Particle: LDL Plus a Second Protein
Lp(a) is assembled in the liver and released into the bloodstream as a complete particle. Its core carries cholesterol and triglycerides, much like LDL. Its surface holds apolipoprotein B-100, the same docking protein found on LDL. What separates Lp(a) from ordinary LDL is apolipoprotein(a), a long, sugar-coated protein tethered to apoB-100 by a single disulfide bond.
That extra protein changes the particle's behavior in two ways. First, apolipoprotein(a) closely resembles plasminogen, a protein involved in dissolving blood clots. Because of this structural mimicry, Lp(a) can interfere with the body's clot-clearing machinery and tilt the balance toward clot formation. Second, the particle tends to stick to damaged vessel walls and to inflamed valve tissue.
Lp(a) also ferries oxidized lipids and inflammatory cargo into the artery wall alongside ordinary LDL. One particle therefore delivers a cholesterol load and a clot-promoting, inflammation-priming signal at the same time. In plain terms, Lp(a) behaves like an LDL particle with a sticky, pro-clotting tail.
Why One Blood Test Changes the Picture
Standard lipid panels report total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. None of these directly captures Lp(a), because Lp(a) cholesterol is bundled into the LDL or "non-HDL" numbers. A person can have a reassuring LDL value and still carry a high Lp(a) burden.
Roughly one in five people worldwide carries an elevated Lp(a) level, according to major cardiology societies. The distribution is heavily skewed by genetics. Blood levels are about 90 percent determined by inheritance and stay largely stable across adulthood, unlike LDL, which shifts with diet, weight, and medication.
This stability is diagnostically useful. A single measurement taken during a routine visit usually reflects a person's lifetime exposure. Clinicians generally do not need repeated testing to track Lp(a) the way they track LDL after starting a statin.
The measurement itself is reported in two common ways. Many labs report Lp(a) mass in milligrams per deciliter (mg/dL). Others report particle number in nanomoles per liter (nmol/L). The two units are not interchangeable with a simple conversion factor, because apolipoprotein(a) comes in different sizes that carry different amounts of mass. This is a professional caveat worth knowing: a result should be interpreted using the units and reference range from the reporting lab, not a home-made conversion.
When Risk Concentrates: Edge Cases
Elevated Lp(a) is not evenly distributed. Certain groups carry higher average levels, including people of African ancestry and some South Asian populations. Within families, the trait clusters strongly, so a high result in one person raises the question of testing close relatives.
Some clinical situations make testing especially informative. These include premature cardiovascular disease, such as a heart attack before age 55 in men or before 65 in women. They also include a personal or family history of early heart disease despite normal-looking cholesterol, and inherited high LDL caused by familial hypercholesterolemia.
Aortic valve disease is another edge case. Lp(a) deposits in the aortic valve and is linked to faster progression of calcific aortic stenosis, a narrowing that can eventually require valve replacement. The connection is well documented, though the effect size varies across studies and is not a reliable prediction for any single person.
Recurrent stroke without a clear cause is a further scenario where testing is often considered. Here the evidence is more mixed. Some studies link high Lp(a) to stroke, but the strength of that link and the benefit of acting on it remain debated, so test results should be weighed alongside the full clinical picture rather than treated as a standalone explanation.
Five Things People Get Wrong About Lp(a)
A few misconceptions reliably surface in clinic and online. Each one deserves a direct correction.
Misconception: a normal LDL means Lp(a) is fine. Reality: lipid panels do not measure Lp(a), and a high Lp(a) can hide behind a normal LDL value. Misconception: diet and exercise will lower Lp(a). Reality: lifestyle measures barely move Lp(a); genetics dominate. Healthy habits still matter for overall cardiovascular risk. Misconception: Lp(a) rises and falls like other cholesterol. Reality: levels are largely stable over a lifetime, so one test usually suffices. Misconception: a high Lp(a) guarantees a heart attack. Reality: it raises risk but does not determine outcomes; other factors such as blood pressure, smoking, and diabetes matter too. Misconception: any Lp(a) result above zero is dangerous. Reality: risk rises with higher levels, and the threshold used to flag concern depends on the guideline and the lab's units.
The last point is the counterintuitive one. A mildly elevated Lp(a) is common and often clinically minor, while very high levels carry much more weight. The number's meaning depends on where it falls on the distribution, not simply on whether it is present.
Comparing Risk Markers and Treatment Options
Lp(a) is one risk marker among several. It differs from LDL in how it is inherited, how it responds to treatment, and how it is measured. The table below compares the main cholesterol-related markers and the current state of Lp(a)-directed therapy.
| Marker or option | What it measures | Inherited component | Responds to lifestyle | Responds to statins | Notes |
|---|---|---|---|---|---|
| LDL cholesterol | Cholesterol carried by LDL particles | Moderate | Strongly | Strongly | Standard of care target |
| HDL cholesterol | Cholesterol carried by HDL particles | Moderate | Partly | Little | Low levels linked to risk |
| Triglycerides | Fat carried in blood | Moderate | Strongly | Partly | Diet and weight sensitive |
| Lp(a) | LDL-like particle plus apolipoprotein(a) | Very high | Minimally | Minimally | Measured separately |
| Statin therapy | Lowers LDL | Not applicable | Not applicable | Yes | Little effect on Lp(a) |
| Lp(a)-directed therapies | Targets apolipoprotein(a) | Not applicable | Not applicable | Not applicable | Under investigation; not routine care |
The treatment column reflects the state of the evidence rather than a prescription. Statins lower LDL effectively but do not meaningfully lower Lp(a). Therapies designed to specifically reduce apolipoprotein(a) production are in clinical development, and some have shown substantial reductions in trials. Their effect on heart attacks and strokes, and their availability and price, are not yet established for routine use.
The Timeline of Risk and Testing
Lp(a) exposure begins early and accumulates over decades. The table below outlines the general time course from inheritance to clinical consequence.
| Stage | What happens | Typical timing |
|---|---|---|
| Genetic inheritance | Variants set apolipoprotein(a) size and production rate | At conception |
| Childhood levels | Lp(a) is present and tracks with adult levels | Childhood onward |
| Stable adult level | Levels plateau and stay largely fixed | Young adulthood |
| Silent vascular exposure | Particle deposits in arteries and valves | Decades |
| First clinical event | Heart attack, stroke, or valve narrowing may appear | Middle to older age |
| Testing opportunity | Lp(a) measured once, often after a clue appears | Variable |
| Family screening | Relatives tested after a high result | After index case |
The key message is that risk accrues silently. A person born with high Lp(a) may have decades of exposure before symptoms appear, which is why early identification in the right clinical context matters.
Practical Steps After a High Result
There is no universal threshold that applies to everyone, and different guidelines set different cutoffs. A common approach is to flag levels roughly at or above 50 mg/dL, or at or above 125 nmol/L, as elevated, while some expert groups use a lower cutoff for additional risk stratification. These numbers should be reconciled with the reporting lab's own reference range and the treating clinician's judgment, not applied as a rigid rule.
Concrete actions include the following. Confirm the result in the lab's reported units and avoid converting between mg/dL and nmol/L. Review the full cardiovascular risk picture, including blood pressure, smoking status, diabetes, and family history. Discuss whether close relatives should be tested, since the trait runs in families. Intensify control of modifiable risk factors, because lowering LDL, blood pressure, and smoking exposure still reduces overall risk even when Lp(a) cannot be changed.
For people with established heart disease, clinicians sometimes set more aggressive LDL targets when Lp(a) is high. That decision belongs to the treating team and depends on the whole picture, not on the Lp(a) value alone.
What Remains Uncertain
The biology of Lp(a) is well described, but several practical questions remain open. The exact level at which risk becomes clinically meaningful varies by guideline and population. The benefit of specifically lowering Lp(a) on heart attacks and strokes has not yet been confirmed in outcome trials. The best way to standardize measurement across labs is still being refined, and the mg/dL versus nmol/L issue complicates comparisons across studies.
For these reasons, Lp(a) testing is best used as one input into a broader risk assessment rather than as a standalone verdict. A high result is a reason to look harder at modifiable risk, not a diagnosis in itself. A normal result does not erase other risk factors.
This article is general educational information, not a diagnosis or treatment plan. It does not promise any outcome. Discuss Lp(a) testing and any changes to your care with a qualified clinician who can review your full history and local guidance. If you have chest pain, stroke symptoms, or another emergency, contact local emergency services immediately.